COVID-19

[Test7]

Coronavirus Disease (COVID-19) Information Center

​

What you need to know about the virus to protect you and your family?

Everyone is talking about coronavirus disease (COVID-19), and everywhere you look there’s information on the virus and how to protect yourself from it. Knowing the facts is key to being properly prepared and protecting yourself and your loved ones. Sadly, there’s a lot of information out there that is incorrect. Misinformation during a health crisis leaves people unprotected and vulnerable to the disease and spreads fear and stigmatization.

Be sure to get your facts from reliable sources, like UNICEF and the World Health Organization. UNICEF is working with global health experts around the clock to provide accurate information. Information you can trust is grounded in the latest scientific evidence. We’ll continue to provide the latest updates, explainers for parents and teachers, and resources for media as new information becomes available, so check back to stay informed of the best ways to protect yourself and your family.

Please help us fight misinformation about COVID-19. Share this information with your family, friends and colleagues to help ensure people have the facts about COVID-19 and can protect their health.

 

[Test7]

What is a ‘novel’ coronavirus?

A novel coronavirus (CoV) is a new strain of coronavirus.
The disease caused by the novel coronavirus first identified in Wuhan, China, has been named coronavirus disease 2019 (COVID-19) – ‘CO’ stands for corona, ‘VI’ for virus, and ‘D’ for disease. Formerly, this disease was referred to as ‘2019 novel coronavirus’ or ‘2019-nCoV.’
The COVID-19 virus is a new virus linked to the same family of viruses as Severe Acute Respiratory Syndrome (SARS) and some types of common cold.
COVID-19 has been described as a pandemic by the World Health Organization. What does that mean?
Characterizing COVID-19 as a pandemic is not an indication that the virus has become deadlier. Rather, it’s an acknowledgement of the disease’s geographical spread.
UNICEF has been preparing and responding to the epidemic of COVID-19 around the world, knowing that the virus could spread to children and families in any country or community. UNICEF will continue working with governments and our partners to stop transmission of the virus, and to keep children and their families safe.
There’s a lot of information online. What should I do?

There are a lot of myths and misinformation about coronavirus being shared online – including on how COVID-19 spreads, how to stay safe, and what to do if you’re worried about having contracted the virus.
So, it’s important to be careful where you look for information and advice. This explainer contains information and recommendations on how to reduce the risk of infection, whether you should take your child out of school, whether it’s safe for pregnant women to breastfeed, and precautions to take when traveling. UNICEF has also launched a portal where you can find more information and guidance about COVID-19. In addition, the WHO has a useful section addressing some of the most frequently asked questions.
It’s also advisable to keep up to date on travel, education and other guidance provided by your national or local authorities for the latest recommendations and news.
How does the COVID-19 virus spread?

The virus is transmitted through direct contact with respiratory droplets of an infected person (generated through coughing and sneezing), and touching surfaces contaminated with the virus. The COVID-19 virus may survive on surfaces for several hours, but simple disinfectants can kill it.
What are the symptoms of coronavirus?

Symptoms can include fever, cough and shortness of breath. In more severe cases, infection can cause pneumonia or breathing difficulties. More rarely, the disease can be fatal.
These symptoms are similar to the flu (influenza) or the common cold, which are a lot more common than COVID-19. This is why testing is required to confirm if someone has COVID-19. It’s important to remember that key prevention measures are the same – frequent hand washing, and respiratory hygiene (cover your cough or sneeze with a flexed elbow or tissue, then throw away the tissue into a closed bin). Also, there is a vaccine for the flu – so remember to keep yourself and your child up to date with vaccinations.
How can I avoid the risk of infection?
Here are four precautions you and your family can take to avoid infection:
UNICEF
What is the best way to wash hands properly?

Step 1: Wet hands with running water
Step 2: Apply enough soap to cover wet hands
Step 3: Scrub all surfaces of the hands – including back of hands, between fingers and under nails – for at least 20 seconds.
Step 4: Rinse thoroughly with running water
Step 5: Dry hands with a clean cloth or single-use towel
Wash your hands often, especially before eating; after blowing your nose, coughing, or sneezing; and going to the bathroom.
If soap and water are not readily available, use an alcohol-based hand sanitizer with at least 60% alcohol. Always wash hands with soap and water, if hands are visibly dirty.
Should I wear a medical mask?

The use of a medical mask is advised if you have respiratory symptoms (coughing or sneezing) to protect others. If you don’t have any symptoms, then there is no need to wear a mask.
If masks are worn, they must be used and disposed of properly to ensure their effectiveness and to avoid any increased risk of transmitting the virus.
The use of a mask alone is not enough to stop infections and must be combined with frequent hand washing, covering sneezes and coughs, and avoiding close contact with anyone with cold or flu-like symptoms (coughing, sneezing, fever).
Does COVID-19 affect children?

This is a new virus and we do not know enough yet about how it affects children or pregnant women. We know it is possible for people of any age to be infected with the virus, but so far there have been relatively few cases of COVID-19 reported among children. The virus is fatal in rare cases, so far mainly among older people with pre-existing medical conditions.

 

[Test7]

What should I do if my child has symptoms of COVID-19?

Seek medical attention, but remember that it’s flu season in the Northern Hemisphere, and symptoms of COVID-19 such as cough or fever can be similar to those of the flu, or the common cold – which are a lot more frequent.
Continue to follow good hand and respiratory hygiene practices like regular handwashing, and keep your child up to date with vaccinations – so that your child is protected against other viruses and bacteria causing diseases.
As with other respiratory infections like the flu, seek care early if you or your child are having symptoms, and try to avoid going to public places (workplace, schools, public transport), to prevent it spreading to others.
What should I do if a family member displays symptoms?

You should seek medical care early if you or your child has a fever, cough or difficulty breathing. Consider calling ahead to tell your health care provider if you have traveled to an area where COVID-19 has been reported, or if you have been in close contact with someone with who has traveled from one of these areas and has respiratory symptoms.
Should I take my child out of school?

If your child is having symptoms, seek medical care, and follow the instructions from the health care provider. Otherwise, as with other respiratory infections like the flu, keep your child well rested at home while symptomatic, and avoid going to public places, to prevent spread to others.
If your child isn’t displaying any symptoms such as a fever or cough – and unless a public health advisory or other relevant warning or official advice has been issued affecting your child’s school – it’s best to keep your child in class.
Instead of keeping children out of school, teach them good hand and respiratory hygiene practices for school and elsewhere, like frequent handwashing (see below), covering cough or sneeze with a flexed elbow or tissue, then throwing away the tissue into a closed bin, not touching their eyes, mouths or noses if they haven’t properly washed their hands.
What precautions should I take for my family if we travel?

Anyone planning a trip overseas should always check the travel advisory for their destination country for any restrictions on entry, quarantine requirements on entry, or other relevant travel advice.
In addition to taking standard travel precautions, and in order to avoid being quarantined or denied re-entry into your home country, you are also advised to check the latest COVID-19 update on the International Air Transport Association website, which includes a list of countries and restriction measures.
While traveling, all parents should follow standard hygiene measures for themselves and their children: Wash hands frequently or use an alcohol-based sanitizer with at least 60 per cent alcohol, practice good respiratory hygiene (cover your mouth and nose with your bent elbow or tissue when you cough or sneeze and immediately dispose of the used tissue) and avoid close contact with anyone who is coughing or sneezing. In addition, it is recommended that parents always carry a hand sanitizer, pack of disposable tissues, and disinfecting wipes.
Additional recommendations include: Clean your seat, armrest, touchscreen, etc. with a disinfecting wipe once inside an aircraft or other vehicle. Also use a disinfecting wipe to clean key surfaces, doorknobs, remote controls, etc at the hotel or other accommodation where you and your children are staying.
Can pregnant women pass coronavirus to unborn children?

At this time, there is not enough evidence to determine whether the virus is transmitted from a mother to her baby during pregnancy, or the potential impact this may have on the baby. This is currently being investigated. Pregnant women should continue to follow appropriate precautions to protect themselves from exposure to the virus, and seek medical care early, if experiencing symptoms, such as fever, cough or difficulty breathing.

Is it safe for a mother to breastfeed if she is infected with coronavirus?

All mothers in affected and at-risk areas who have symptoms of fever, cough or difficulty breathing, should seek medical care early, and follow instructions from a health care provider.
Considering the benefits of breastfeeding and the insignificant role of breastmilk in the transmission of other respiratory viruses, the mother can continue breastfeeding, while applying all the necessary precautions.
For symptomatic mothers well enough to breastfeed, this includes wearing a mask when near a child (including during feeding), washing hands before and after contact with the child (including feeding), and cleaning/disinfecting contaminated surfaces – as should be done in all cases where anyone with confirmed or suspected COVID-19 interacts with others, including children.
If a mother is too ill, she should be encouraged to express milk and give it to the child via a clean cup and/or spoon – all while following the same infection prevention methods.
I’m worried about bullying, discrimination and stigmatization. What’s the best way to talk about what’s happening?

It’s understandable if you’re feeling worried about the coronavirus. But fear and stigma make a difficult situation worse. For example, there are reports emerging from around the world of individuals, particularly of Asian descent, being subject to verbal or even physical abuse.
Public health emergencies are stressful times for everyone affected. It’s important to stay informed and to be kind and supportive to each other. Words matter, and using language that perpetuates existing stereotypes can drive people away from getting tested and taking the actions they need to protect themselves and their communities.
Here are some do’s and don’ts for how to talk about the coronavirus with your children, family and friends:

DO: talk about the new coronavirus disease (COVID-19)
DON’T: attach locations or ethnicity to the disease. Remember, viruses can’t target people from specific populations, ethnicities, or racial backgrounds.

DO: talk about “people who have COVID-19”, “people who are being treated for COVID-19”, “people who are recovering from COVID-19” or “people who died after contracting COVID-19”
DON’T: refer to people with the disease as “COVID-19 cases” or “victims”

DO: talk about people “acquiring” or “contracting” COVID-19
DON’T: talk about people “transmitting COVID-19” “infecting others” or “spreading the virus” as it implies intentional transmission and assigns blame.

DO: speak accurately about the risk from COVID-19, based on scientific data and latest official health advice
DON’T: repeat or share unconfirmed rumours, and avoid using hyperbolic language designed to generate fear like “plague”, “apocalypse” etc.

DO: talk positively and emphasise the importance of effective prevention measures, including following our tips on handwashing. For most people this is a disease they can overcome. There are simple steps we can all take to keep ourselves, our loved ones and the most vulnerable safe.

 

[Saithan]

https://twitter.com/i/web/status/1297996139984191489

Interesting to see turks achieving recognition in different venues of life.

 

[Mis_TR_Like]

Turkish military runs over 500,000 virus tests - Türkiye News

The Turkish military has conducted more than 500,000 tests for COVID-19 on personnel to date, the defense minister has said.

www.google.com

 

[Ryder]

Turkish military runs over 500,000 virus tests - Türkiye News

The Turkish military has conducted more than 500,000 tests for COVID-19 on personnel to date, the defense minister has said.

www.google.com

So good to see the Military comabting the pandemic. Soldiers are always the first ones to suffer from diseases or epidemics hence this experience allowed modern medicine to advance.

 

[Saithan]

Turkey not counting COVID-19 cases 'unless there are symptoms'

Health Minister Fahrettin Koca sought to draw a difference between COVID-19 "patients" and "cases" after an opposition MP suggested the true figures were 20 times higher

www.euronews.com

So AKP isn't counting ppl who have tested positive for Covid-19 because they show no symptoms...

I think they're forgetting that they can infect others who can develop symptoms.... Idiocy ?

 

[Anmdt]

Turkey not counting COVID-19 cases 'unless there are symptoms'

Health Minister Fahrettin Koca sought to draw a difference between COVID-19 "patients" and "cases" after an opposition MP suggested the true figures were 20 times higher

www.euronews.com

So AKP isn't counting ppl who have tested positive for Covid-19 because they show no symptoms...

I think they're forgetting that they can infect others who can develop symptoms.... Idiocy ?

It is worse in either way:
Commoners (this term fits here just perfect) are not tested if they dont show symptoms, they are even not tested if symptoms are not heavy despite of having covid positive within family /work circle,
And Minister of Health just has told they are not counting covid positive patients without symptoms in numbers,
Which means, there are quite many people (since he needed to unveil this detail to relieve doubts on numbers) who has access to tests and they can do test whenever they want even if they haven't contacted covid positives, or showing symptoms.
There are people who has to get a test (for official reasons, like traveling), but i dont think these are in high numbers to cause a confusion in numbers.

 

[Zafer]

"Hi, my name is Corona, how are you?". At some point along the pandemic timeline, I wanted to say these words, LOL.

Death numbers are what shows it all. Second comes active cases which are people under healthcare. As long as active cases don't turn into casualties, it's fine.

 

[Saithan]

"Hi, my name is Corona, how are you?". At some point along the pandemic timeline, I wanted to say these words, LOL.

Death numbers are what shows it all. Second comes active cases which are people under healthcare. As long as active cases don't turn into casualties, it's fine.

But the problem is that ppl are not tested. So we have a lot ppl walking around as carriers and infect others.

All ppl positive should be in isolation and be tested 2 -3weeks later and hopefully be covid free.

Cocvid cases go up because ppl are careless and we don’t have a trace or testings.

I’ve been tested twice and my wife 4-6 times since she’s exposed in the healthcare sector.

We’re negative, allaha sukur

 

[Combat-Master]

 

[Zafer]

But the problem is that ppl are not tested. So we have a lot ppl walking around as carriers and infect others.

All ppl positive should be in isolation and be tested 2 -3weeks later and hopefully be covid free.

Cocvid cases go up because ppl are careless and we don’t have a trace or testings.

I’ve been tested twice and my wife 4-6 times since she’s exposed in the healthcare sector.

We’re negative, allaha sukur

I think there must be a balance between cause and response, there is no point in alarming people. I have never been tested but I know I have been down with Covid-19. It was around the end of October last year, I met a long lost neighbor and junior of mine from school who came from abroad, from far east where he works. Like a couple of weeks after an unwary warm welcome I gave to my friend I had a coughing disease the kind of which I never had over decades. I waited for the cough to go away by itself which lasted around two weeks and I was finally convinced to see a doctor but getting an appointment was not possible because it was near the new years eve. When I finally got an appointment 80% of symptoms had disappeared. Fearing from the worst I had a breather when I was told there wasn't anything wrong with the lung department. There was no talk of Covid-19 at that time.

 

[Bogeyman]

Kovid-19 map for Germany
The map was published today.

 

[Bogeyman]

https://twitter.com/i/web/status/1323303110320787458

 

[Saithan]

Mink farms in Denmark, mutation of COVID-19 from mink to human is resulting in that region being shut in. Denmark is talking about acting in time to avoid becoming a wuhan.

 

[Test7]

PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19 ACHIEVED SUCCESS IN FIRST INTERIM ANALYSIS FROM PHASE 3 STUDY​

Monday, November 09, 2020 - 06:45am

• Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis
• Analysis evaluated 94 confirmed cases of COVID-19 in trial participants
• Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected
• Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November
• Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201109005539/en/
NEW YORK & MAINZ, GERMANY--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study.

After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the DMC performed its first analysis on all cases. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at 7 days after the second dose. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule. As the study continues, the final vaccine efficacy percentage may vary. The DMC has not reported any serious safety concerns and recommends that the study continue to collect additional safety and efficacy data as planned. The data will be discussed with regulatory authorities worldwide.

“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the DMC performed its first analysis on all cases. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at 7 days after the second dose. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule. As the study continues, the final vaccine efficacy percentage may vary. The DMC has not reported any serious safety concerns and recommends that the study continue to collect additional safety and efficacy data as planned. The data will be discussed with regulatory authorities worldwide.

“I want to thank the thousands of people who volunteered to participate in the clinical trial, our academic collaborators and investigators at the study sites, and our colleagues and collaborators around the world who are dedicating their time to this crucial endeavor,” added Bourla. “We could not have come this far without the tremendous commitment of everyone involved.”

“The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent COVID-19. This is a victory for innovation, science and a global collaborative effort,” said Prof. Ugur Sahin, BioNTech co-founder and CEO. “When we embarked on this journey 10 months ago this is what we aspired to achieve. Especially today, while we are all in the midst of a second wave and many of us in lockdown, we appreciate even more how important this milestone is on our path towards ending this pandemic and for all of us to regain a sense of normality. We will continue to collect further data as the trial continues to enroll for a final analysis planned when a total of 164 confirmed COVID-19 cases have accrued. I would like to thank everyone who has contributed to make this important achievement possible.”
The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020. Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds. The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued. The study also will evaluate the potential for the vaccine candidate to provide protection against COVID-19 in those who have had prior exposure to SARS-CoV-2, as well as vaccine prevention against severe COVID-19 disease. In addition to the primary efficacy endpoints evaluating confirmed COVID-19 cases accruing from 7 days after the second dose, the final analysis now will include, with the approval of the FDA, new secondary endpoints evaluating efficacy based on cases accruing 14 days after the second dose as well. The companies believe that the addition of these secondary endpoints will help align data across all COVID-19 vaccine studies and allow for cross-trial learnings and comparisons between these novel vaccine platforms. The companies have posted an updated version of the study protocol at https://www.pfizer.com/science/coronavirus.

Pfizer and BioNTech are continuing to accumulate safety data and currently estimate that a median of two months of safety data following the second (and final) dose of the vaccine candidate – the amount of safety data specified by the FDA in its guidance for potential Emergency Use Authorization – will be available by the third week of November. Additionally, participants will continue to be monitored for long-term protection and safety for an additional two years after their second dose.
Along with the efficacy data generated from the clinical trial, Pfizer and BioNTech are working to prepare the necessary safety and manufacturing data to submit to the FDA to demonstrate the safety and quality of the vaccine product produced.
Based on current projections we expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.
Pfizer and BioNTech plan to submit data from the full Phase 3 trial for scientific peer-review publication.

About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Pfizer Disclosure Notice
The information contained in this release is as of November 9, 2020. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine, the BNT162 mRNA vaccine program, and modRNA candidate BNT162b2 (including qualitative assessments of available data, potential benefits, expectations for clinical trials, anticipated timing of clinical trial readouts and regulatory submissions and anticipated manufacturing, distribution and supply), that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preliminary and interim data, (including the Phase 3 interim data that is the subject of this release), including the possibility of unfavorable new preclinical or clinical trial data and further analyses of existing preclinical or clinical trial data; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications; whether regulatory authorities will be satisfied with the design of and results from these and future preclinical and clinical studies; whether and when any biologics license and/or emergency use authorization applications may be filed in any jurisdictions for BNT162b2 or any other potential vaccine candidates; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine candidate’s benefits outweigh its known risks and determination of the vaccine candidate’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners or third-party suppliers; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine candidate’s ultra-low temperature formulation and attendant storage, distribution and administration requirements, including risks related to handling after delivery by Pfizer; the risk that we may not be able to successfully develop non-frozen formulations; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or have access to logistics or supply channels commensurate with global demand for any potential approved vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine candidate within the projected time periods indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.

BioNTech Forward-looking statements
This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine; our expectations regarding the potential characteristics of BNT162b2 in our Phase 2/3 trial and/or in commercial use based on data observations to date; the expected timepoint for additional readouts on efficacy data of BNT162b2 in our Phase 2/3 trial; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any potential Emergency Use Authorization; the timing for submission of manufacturing data to the FDA; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimates for 2020 and 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties. For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report on Form 20-F filed with the SEC on March 31, 2020, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study | Pfizer

Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis Analysis evaluated 94 confirmed cases of COVID-19 in trial participants Study enrolled 43,538 participants, with...

www.pfizer.com

 

[Test7]

I did not know that BioNTech firm belongs to a Turk (Prof. Dr. Uğur Şahin)

 

[Saithan]

I did not know that BioNTech firm belongs to a Turk (Prof. Dr. Uğur Şahin)

and his wife

Real patriots, they conducted trials in Turkey as well. I just don't know if they'll establish production in Turkey, but I believe they will.

 

[Test7]

and his wife

Real patriots, they conducted trials in Turkey as well. I just don't know if they'll establish production in Turkey, but I believe they will.

He said that they can produce how many vaccine turkey needs in first quarter of 2021

 

[Saithan]

BioNTech’s German-Turkish founder says will deliver coronavirus vaccines worldwide - Türkiye News

BioNTech, which has developed a 90 percent effective coronavirus vaccine, will produce 1.3 billion doses by the end of 2021 and make it available worldwide, the Turkish owner of the German pharmaceutical company BioNTech said on Nov. 11.

www.hurriyetdailynews.com

Turkish Health Ministry has not met with this guy...... Fire the minister.